Progress of research on Janus kinase inhibitors in treatment of ulcerative colitis / 胃肠病学
Chinese Journal of Gastroenterology
; (12): 243-248, 2023.
Article
in Zh
| WPRIM
| ID: wpr-1016032
Responsible library:
WPRO
ABSTRACT
Ulcerative colitis (UC) is a chronic inflammatory bowel disease caused by multiple factors, and its etiology and pathogenesis are not fully understood. Janus kinases (JAK) are non‑transmembrane tyrosine kinases that play a key role in many immune‑related cytokine signaling pathways. JAK‑STATs signaling pathway is a cytokine‑mediated signaling pathway, which is involved in many important biological processes such as cell proliferation, differentiation, apoptosis and immune regulation. JAK inhibitors are small molecule drugs that can be administered orally and are relatively inexpensive, therefore, JAK inhibitors may become a new target for the treatment of UC. This article reviewed progress of research on the efficacy and safety of small molecule JAK inhibitors in treatment of UC.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Gastroenterology
Year:
2023
Type:
Article